NASDAQ$PAHC

Phibro Animal Health Corporation · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Phibro Animal Health Corporation reported mixed Q4 2023 results with a slight decrease in net sales but an increase in net income and EPS.

Phibro Animal Health Corporation reported Q4 2023 results with net sales of $255.0 million, a slight decrease of $0.2 million. However, net income increased by $4.0 million to $11.5 million, and diluted EPS also increased by $0.10 to $0.28. The company provided FY 2024 guidance, projecting net sales of $1.0 to $1.05 billion and adjusted EBITDA of $115 to $121 million.

  • Net sales decreased slightly by $0.2 million to $255.0 million.
  • Net income increased significantly by $4.0 million to $11.5 million.
  • Diluted EPS increased by $0.10 to $0.28.
  • The company is optimistic about opportunities related to vaccines and nutritional specialties in fiscal year 2024.

Headline financials

Total Revenue

$255M

Previous: $255M-0.1%
EPS (adj)

$0.38

Previous: $0.36+5.6%
Net Income

$11.5M

Previous: $7.5M+53.3%
Operating Income

$23.8M

Previous: $14.5M+64.2%
Gross Profit

$76.7M

Previous: $78.5M-2.3%
Cash & Equivalents

$41.3M

Previous: $74.2M-44.4%
Total Assets

$971M

Previous: $932M+4.3%

Revenue & EPS history

Phibro · Revenue · Quarterly

$255M

Q4 2023-0.1%vs Q4 2022
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Phibro · $255M total across 3 segments · Q4 2023

  • Animal Health
    $177M
  • Mineral Nutrition
    $58.4M
  • Performance Products
    $19.9M

Forward guidance

Phibro Animal Health Corporation provided financial guidance for the year ending June 30, 2024, projecting net sales of $1.0 to $1.05 billion and adjusted EBITDA of $115 to $121 million.

Tailwinds

  • Net sales of $1.0 to $1.05 billion, 5% growth
  • Net income of $31 to $36 million, 2% growth
  • Diluted EPS of $0.76 to $0.90, 2% growth
  • Adjusted EBITDA of $115 to $121 million, 5% growth
  • Adjusted net income of $45 to $51 million, 2% decline

Headwinds

  • Adjusted diluted EPS of $1.12 to $1.27, 2% decline
  • Adjusted effective tax rate of 33% to 35%
  • Mineral Nutrition and Performance Products segments are projected to deliver financial performance in line with the prior fiscal year.
  • Assumed projected foreign exchange rates applicable to fiscal year 2024.
  • Planned year-over-year increase of $3 million, or 9%, in strategic investments.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-0.1%

Avg return

Earnings day

+1.0%

Avg return

5 days after

-1.4%

Avg return

30 days after

56%

29 / 52 earnings

Positive

+22.0%

Q2 2026

Best reaction

-31.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-26.1%-37.5%-44.6%
Q2 2026+22.0%+26.2%+16.9%
Q1 2026+4.7%+10.2%-4.8%
Q3 2025+14.7%+26.9%+24.2%
Q2 2025+9.9%+16.8%+5.7%
Q1 2025+2.8%+11.8%+1.6%
Q4 2024+1.9%-0.3%+4.8%
Q3 2024+5.5%+8.0%+2.3%
Q2 2024+5.9%+12.5%+19.1%
Q1 2024-18.9%-19.3%-8.4%
Q4 2023-5.8%-2.0%-13.8%
Q3 2023-8.4%-8.0%-12.0%
Q2 2023-0.9%-1.3%-4.7%
Q1 2023-5.5%-8.0%-14.2%
Q4 2022-4.8%-7.4%-24.4%
Q3 2022-4.0%-2.9%-0.5%
Q2 2022+5.7%+13.7%+6.0%
Q1 2022-0.8%-0.3%-10.1%
Q4 2021-5.0%-1.0%-10.2%
Q3 2021+8.1%+3.9%+14.7%
Q2 2021+7.3%+7.9%+7.5%
Q1 2021+4.5%+8.1%+10.0%
Q4 2020+0.9%+4.6%-13.0%
Q3 2020-4.6%-4.8%+15.7%
Q2 2020+16.9%+14.0%+12.5%
Q1 2020-8.1%-4.8%-0.0%
Q4 2019-31.5%-35.0%-32.5%
Q3 2019-19.7%-17.2%-17.0%
Q2 2019-6.4%-10.4%-11.8%
Q1 2019-8.7%-12.5%-22.1%
Q4 2018-3.0%-7.0%-15.3%
Q3 2018+4.2%+3.2%+9.7%
Q2 2018+6.8%+4.4%+16.0%
Q1 2018-4.9%-8.2%-12.9%
Q4 2017-5.1%-2.4%-0.9%
Q3 2017+6.0%+10.9%+18.4%
Q2 2017+7.0%+12.1%+0.2%
Q1 2017+11.3%+8.9%+3.4%
Q4 2016+15.4%+24.9%+28.9%
Q3 2016-10.3%
Q2 2016-18.2%
Q1 2016-3.4%
Q4 2015-5.3%
Q3 2015+7.9%
Q2 2015+6.5%
Q1 2014+5.5%
Q1 2015+7.4%
Q2 2014+0.3%
Q4 2014+12.6%
Q4 2013+1.0%
Q3 2013+1.0%
Q3 2014+1.0%
Q2 2013
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro